Symposium: Drug Development from Bench to Bedside @UZ Gent

Thursday 25 April 2024

• 12.00 | Registration with light lunch
• 13.00 | Welcome  | Piet Hoebeke, Dean of the Faculty of Medicine and Health Sciences, Ghent University
• 13.15 | New directions/new mode of actions studied in phase I trials | Dr Rachel Galot, Cliniques Universitaires Saint-Luc 
• 13.45 | Statistical interpretation of clinical trial data | Dr Alexander Decruyenaere, Ghent University Hospital
• 14.15 | Challenges in development of CAR-T therapies in pediatrics | Prof. Dr Claudia Rössig, University Hospital Münster
• 14.45 | Melanoma: more progress, more hope, more time | Dr Celine Jacobs, Ghent University Hospital    
• 15.15 | Tea break & visit exhibitors
• 15.45 | Challenges in performing clinical trials in low incidence disease | Prof. Dr Sylvie Rottey and Dr Levi Hoste, Ghent University Hospital
• 16.15 | Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM | Prof. Dr Ina Oehme, DKFZ Heidelberg
• 16.45 | Closing word | Philippe Van Rompaey, Ghent University Hospital
• 17.15 | Networking drink

Friday 26 April 2024

• 08.30 | Registration with coffee
• 09.00 | Welcome | Prof. Dr Frank Vermassen, Chief Physician Ghent University Hospital 
• 09.15 | Clinical Trials in Rare Diseases | Dr Eva Degraeuwe, Ghent University and Ghent University Hospital
• 09.45 | CHIM story – human challenge trials | Prof. Pierre Van Damme, University of Antwerp
• 10.15 | First learnings from the European clinical trial regulation and its impact on research in Belgium | Tim Weglewski, IQVIA
• 10.45 | Coffee break & visit exhibitors
• 11.30 | Gene therapies in ophthalmology | Prof. Dr Bart Leroy, Ghent University Hospital 
• 12.00 | Patients as partners: the power of a Patient Advisory Board for clinical research (PAWO) | 
  Wendy Van de Velde, PAWO, Ghent University Hospital (presentation in Dutch)
• 12.30 | Networking lunch & visit exhibitors
• 13.30 | Leveraging RCTs to unravel fundamental biology: lessons from COVID-19 | Dr Karel Van Damme, Ghent University, IRC 
• 14.00 | Future GMP facility for Gene and Cell therapy at U(Z) Gent | Dr Tim Desmet, Ghent University
• 14.30 | Sarcoma models database/website | Prof. Dr Olivier De Wever, Ghent University
• 15.00 | Cochrane reviews: content – method – purpose. Post marketing surveillance | Dr Ellen Van Leeuwen, Ghent University
• 15.30 | Closing word | Prof. Dr Sylvie Rottey
• 16.00 | Farewell reception